Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197104 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8613098 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL6899407 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8613264 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL197971 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL6258951 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8090318 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8614288 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL345851 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL8613060 | 1.00 | LMNA (0.40) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032669-B | Orthoester compositions for affinity purification of oligonucleotides | 安捷伦科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3668883-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Agilent Technologies, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. | 2020-06-11 | — | — | US | disclosed |
| CN-111032669-A | Ortho ester compositions for affinity purification of oligonucleotides | 安捷伦科技有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019036029-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | AGILENT TECHNOLOGIES, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-0837085-A1 | POLYCARBONATE-BASE POLYMER, PRODUCTION PROCESS, RESIN COATING FLUID PREPARED THEREFROM, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR PREPARED THEREFROM | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190129-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | LMNA 3111/4885THRB 688/4885CA2 4500/4885 |
| US-20200181124-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | LMNA 3111/4885THRB 688/4885CA2 4500/4885 |
| US-11548876-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | LMNA 3111/4885THRB 688/4885CA2 4500/4885 |
| US-20230322742-A1 | ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | RNGTT, OSBPL8, DCLRE1B | LMNA 3111/4885THRB 688/4885CA2 4500/4885 |
| US-11299483-B2 | Orthoester compositions for affinity purification of oligonucleotides | RNGTT, OSBPL8, DCLRE1B | LMNA 3111/4885THRB 688/4885CA2 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.